348 related articles for article (PubMed ID: 12053600)
1. [Mucolytics in acute and chronic respiratory tract disorders. I. Pathophysiology and mechanisms of action].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 2002 Mar; 12(69):245-7. PubMed ID: 12053600
[TBL] [Abstract][Full Text] [Related]
2. [Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 2002 Mar; 12(69):248-52. PubMed ID: 12053601
[TBL] [Abstract][Full Text] [Related]
3. Mucoactive agents for airway mucus hypersecretory diseases.
Rogers DF
Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
[TBL] [Abstract][Full Text] [Related]
4. The pharmacologic approach to airway clearance: mucoactive agents.
Rubin BK
Paediatr Respir Rev; 2006; 7 Suppl 1():S215-9. PubMed ID: 16798570
[TBL] [Abstract][Full Text] [Related]
5. Rationale of airway clearance.
Clarke SW
Eur Respir J Suppl; 1989 Jul; 7():599s-603s. PubMed ID: 2679608
[TBL] [Abstract][Full Text] [Related]
6. The pharmacologic approach to airway clearance: mucoactive agents.
Rubin BK
Respir Care; 2002 Jul; 47(7):818-22. PubMed ID: 12088552
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic possibilities in chronic non-specific respiratory tract diseases. 1. Modification of secretion, inhalation- and respiration therapy, therapy of bronchial obstruction].
Löllgen H; Löllgen-Horres I; von Nieding G
Fortschr Med; 1976 Aug; 94(24):1276-84. PubMed ID: 786833
[No Abstract] [Full Text] [Related]
8. Management of mucus hypersecretion.
Clarke SW
Eur J Respir Dis Suppl; 1987; 153():136-44. PubMed ID: 3322858
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.
Disse B
Novartis Found Symp; 2002; 248():254-72; discussion 272-6, 277-82. PubMed ID: 12568499
[TBL] [Abstract][Full Text] [Related]
10. Ambroxol in the 21st century: pharmacological and clinical update.
Malerba M; Ragnoli B
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1119-29. PubMed ID: 18680446
[TBL] [Abstract][Full Text] [Related]
11. Mucolytics and antioxidant activity.
Strapková A; Nosál'ová G; Franová S
Life Sci; 1999; 65(18-19):1923-5. PubMed ID: 10576438
[TBL] [Abstract][Full Text] [Related]
12. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
Cazzola M; Rogliani P; Calzetta L; Hanania NA; Matera MG
COPD; 2017 Oct; 14(5):552-563. PubMed ID: 28753070
[TBL] [Abstract][Full Text] [Related]
13. Influence of tasuldine and acetylcysteine on mucociliary clearance in patients with chronic airways obstruction.
Dorow P; Weiss T; Felix R; Köhler M
Arzneimittelforschung; 1986; 36(1):131-3. PubMed ID: 3954815
[TBL] [Abstract][Full Text] [Related]
14. Mucolytics, expectorants, and mucokinetic medications.
Rubin BK
Respir Care; 2007 Jul; 52(7):859-65. PubMed ID: 17594730
[TBL] [Abstract][Full Text] [Related]
15. Exacerbations of chronic obstructive pulmonary disease.
Wedzicha JA; Donaldson GC
Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
[TBL] [Abstract][Full Text] [Related]
16. [Inhalation therapy from the modern point of view].
Stadeler HJ
Schweiz Rundsch Med Prax; 1971 Nov; 60(45):1509-12. PubMed ID: 4946731
[No Abstract] [Full Text] [Related]
17. Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature.
Boogaard R; de Jongste JC; Merkus PJ
Pediatr Pulmonol; 2007 Nov; 42(11):989-1001. PubMed ID: 17902149
[TBL] [Abstract][Full Text] [Related]
18. [Use of mucolytic preparations (Mucosolvan) in selected diseases of the upper respiratory tract. Part II].
Szmeja Z; Golusiński W; Mielcarek-Kuchta D; Laczkowska-Przybylska J
Otolaryngol Pol; 1997; 51(5):480-6. PubMed ID: 9557050
[TBL] [Abstract][Full Text] [Related]
19. Improvement of mucociliary transport in smokers by mucolytics.
Olivieri D; Marsico SA; Del Donno M
Eur J Respir Dis Suppl; 1985; 139():142-5. PubMed ID: 3862608
[TBL] [Abstract][Full Text] [Related]
20. [The cleaning system of the airways: physiology, pathophysiology and effects of ambroxol].
Wunderer H; Morgenroth K; Weis G
Med Monatsschr Pharm; 2009 Feb; 32(2):42-7. PubMed ID: 19263911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
